NCT01049893View on ClinicalTrials.gov

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Solid Tumors
Interventions
DRUG

Compound AC220

Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.

Trial Locations (2)

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

02115

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY